1. Home
  2. CDT vs MCVT Comparison

CDT vs MCVT Comparison

Compare CDT & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • MCVT
  • Stock Information
  • Founded
  • CDT 2019
  • MCVT 2007
  • Country
  • CDT United States
  • MCVT United States
  • Employees
  • CDT N/A
  • MCVT N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • MCVT Finance Companies
  • Sector
  • CDT Health Care
  • MCVT Finance
  • Exchange
  • CDT Nasdaq
  • MCVT Nasdaq
  • Market Cap
  • CDT 10.9M
  • MCVT 11.6M
  • IPO Year
  • CDT N/A
  • MCVT N/A
  • Fundamental
  • Price
  • CDT $0.11
  • MCVT $1.85
  • Analyst Decision
  • CDT
  • MCVT
  • Analyst Count
  • CDT 0
  • MCVT 0
  • Target Price
  • CDT N/A
  • MCVT N/A
  • AVG Volume (30 Days)
  • CDT 34.8M
  • MCVT 7.5K
  • Earning Date
  • CDT 11-14-2024
  • MCVT 11-12-2024
  • Dividend Yield
  • CDT N/A
  • MCVT N/A
  • EPS Growth
  • CDT N/A
  • MCVT N/A
  • EPS
  • CDT N/A
  • MCVT 0.05
  • Revenue
  • CDT N/A
  • MCVT $3,234,265.00
  • Revenue This Year
  • CDT N/A
  • MCVT N/A
  • Revenue Next Year
  • CDT N/A
  • MCVT N/A
  • P/E Ratio
  • CDT N/A
  • MCVT $36.44
  • Revenue Growth
  • CDT N/A
  • MCVT N/A
  • 52 Week Low
  • CDT $0.08
  • MCVT $1.76
  • 52 Week High
  • CDT $7.83
  • MCVT $3.88
  • Technical
  • Relative Strength Index (RSI)
  • CDT 52.44
  • MCVT 33.24
  • Support Level
  • CDT $0.08
  • MCVT $1.76
  • Resistance Level
  • CDT $0.10
  • MCVT $2.20
  • Average True Range (ATR)
  • CDT 0.02
  • MCVT 0.09
  • MACD
  • CDT 0.00
  • MCVT -0.02
  • Stochastic Oscillator
  • CDT 33.24
  • MCVT 2.27

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About MCVT Mill City Ventures III Ltd.

Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.

Share on Social Networks: